代谢相关脂肪性肝病患者回肠菌群特征研究*

doi:10.3969/j.issn.1672-5069.2025.03.009

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (3): 354-357.doi: 10.3969/j.issn.1672-5069.2025.03.009

代谢相关脂肪性肝病患者回肠菌群特征研究^*

卫涛涛, 刘天烨, 戴高中

210046 江苏省无锡市南京中医药大学附属无锡医院消化科

收稿日期:2025-01-04 发布日期:2025-05-14
通讯作者: 戴高中,E-mail:daigaozhong@126.com
作者简介:卫涛涛,男,38岁,医学硕士,副主任医师。E-mail:wtttoby@163.com
基金资助:
^*江苏省无锡市卫生健康委青年基金资助项目(编号:Q202161);南京中医药大学科研基金资助项目(编号:XZR2021068)

Characterization of ileal microbiome in patients with metabolic-associated fatty liver disease

Wei Taotao, Liu Tianye, Dai Gaozhong

Department of Gastroenterology, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi 210046, Jiangsu Province, China

Received:2025-01-04 Published:2025-05-14

摘要/Abstract

摘要： 目的探讨代谢相关脂肪性肝病(MAFLD)患者回肠末端菌群特征。方法 2024年1月～2024年11月我院诊治的MAFLD患者54例和健康人18例,均接受FibroScan行受控衰减参数(CAP)检测,使用内镜和特殊装置进镜至回肠取样,采用16S rDNA测序。结果本组MAFLD轻度、中度和重度患者分别为18例、18例和18例;MAFLD患者回肠菌群Alpha多样性升高,苏黎世杆菌占比随病情严重逐步下降,乳杆菌和韦荣氏球菌属丰度下降,而纤毛菌属、普氏菌属和卟啉单胞菌丰度增加。结论 MALFD患者回肠菌群多样性和菌群丰度发生改变,与疾病的严重程度相关。苏黎世杆菌减少,口腔定植菌的迁移可能是MAFLD患者回肠菌群特征表现的原因。

Abstract: Objective The aim of this study was to investigate characteristics of ileal microbiota in patients with metabolic associated fatty liver disease (MAFLD). Methods 54 patients with MAFLD and 18 individuals for physical examination were recruited in our hospital between January 2024 and November 2024, all underwent FibroScan scan for controlled attenuation parameter (CAP) and endoscopy with special device for ileal specimen collection. 16S rDNA sequencing was performed. Results Patients with MAFLD in our series were divided into mild, moderate and severe liver steatosis, with 18 cases in each; patients with MAFLD had an elevated Alpha diversity of ileal flora, with a gradual decrease in percentage of Turicibacter, a reduction in abundance of Lactobacillus and Veillonella, while having an increase in the abundance of Prevotella, Leptotrichia and Porphyromonas. Conclusion The diversity and abundance of ileal microbiota in patients with MAFLD change, which is related to the severity of the entity. The reduction of Turicibacter and the migration of oral colonizing bacteria might be characteristics of the ileal microbiota in patients with MAFLD.

Key words: Metabolic related fatty liver disease, Endoscopic sampling, Ileal flora, Turicibacter bacteria, Flora migration

卫涛涛, 刘天烨, 戴高中. 代谢相关脂肪性肝病患者回肠菌群特征研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 354-357.

Wei Taotao, Liu Tianye, Dai Gaozhong. Characterization of ileal microbiome in patients with metabolic-associated fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(3): 354-357.

参考文献

[1] 范建高, 杨荣. 全球非酒精性脂肪性肝病的流行趋势与疾病负担. 中华消化杂志, 2023, 43(4) : 248-252.
[2] 曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展. 实用肝脏病杂志, 2023, 26(6) : 769-772.
[3] 范建高, 李小英. NAFLD更名MAFLD、MASLD:背景、异同、对策. 中华肝脏病杂志,2023,31(8):789-792.
[4] Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci, 2020, 21(15):5214.
[5] Collins S L, Stine J G, Bisanz J E, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol, 2023, 21(4) : 236-247.
[6] Tang Q, Jin G, Wang G, et al. Current sampling methods for gut microbiota: a call for more precise devices. Front Cell Infect Microbiol, 2020, 10: 151.
[7] 范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) . 实用肝脏病杂志, 2024, 27(4) : 494-510.
[8] Keam S J. Resmetirom: First approval. Drugs, 2024, 84(6) : 729-735.
[9] 薛峰, 魏来. 从代谢谈脂肪性肝病:疾病本源与新药终点再思考. 中华肝脏病杂志, 2023, 31(8) : 785-788.
[10] Gottlieb A, Canbay A. Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression. Cells, 2019, 8(11):532-539.
[11] Wei J, Luo J, Yang F, et al. Cultivated enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine. Gut Microbes, 2024, 16(1): 2351620.
[12] Kemis J H, Linke V, Barrett K L, et al. Genetic determinants of gut microbiota composition and bile acid profiles in mice. PLoS Genet, 2019, 15(8) : e1008073.
[13] Zhong Y, Nyman M, Fåk F. Modulation of gut microbiota in rats fed high-fat diets by processing whole-grain barley to barley malt. Mol Nutr Food Res, 2015, 59(10) : 2066-2076.
[14] Chen Y, Xu C, Huang R, et al. Butyrate from pectin fermentation inhibits intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E-deficient mice. J Nutr Biochem, 2018, 56: 175-182.
[15] Lynch J B, Gonzalez E L, Choy K, et al. Gut microbiota turicibacter strains differentially modify bile acids and host lipids. Nat Commun, 2023, 14(1) : 3669.
[16] Lau H C, Zhang X, Ji F, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. EBioMedicine, 2024, 100: 104952.
[17] Shanahan E R, Zhong L, Talley N J, et al. Characterisation of the gastrointestinal mucosa-associated microbiota: a novel technique to prevent cross-contamination during endoscopic procedures. Aliment Pharmacol Ther, 2016, 43(11) : 1186-1196.
[18] Mottawea W, Butcher J, Li J, et al. The mucosal-luminal interface: an ideal sample to study the mucosa-associated microbiota and the intestinal microbial biogeography. Pediatr Res, 2019, 85(6) : 895-903.
[19] Cui J, Zheng X, Hou W, et al. The study of a remote-controlled gastrointestinal drug delivery and sampling system. Telemed J E Health, 2008, 14(7) : 715-719.
[20] Koziolek M, Grimm M, Becker D, et al. Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the intellicap(©) system. J Pharm Sci, 2015, 104(9) : 2855-2863.

代谢相关脂肪性肝病患者回肠菌群特征研究^*

Characterization of ileal microbiome in patients with metabolic-associated fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘倩, 杨洁, 张静, 宫克, 郭瑞丹. 慢性乙型肝炎合并代谢相关脂肪性肝病患者外周血单个核细胞Galectin-3和Galectin-9水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 338-341.
[2]	董旭, 王超群, 陈怡, 朱彤, 葛玲玲, 徐爱静. 估算葡萄糖处置率评估无糖尿病人群代谢相关脂肪性肝病发生风险效能研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 362-365.
[3]	秦浩, 方春华, 何競, 张磊, 冉斌, 汪丽萍, 张振华. 六种无创评分诊断2型糖尿病合并代谢相关脂肪性肝病患者效能比较^*[J]. 实用肝脏病杂志, 2025, 28(3): 366-369.
[4]	黄嘉伟, 纪雅丽, 周玲, 陈金军. 代谢相关脂肪性肝病患者SAF评分和脂肪肝进展抑制算法应用研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 48-51.
[5]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[6]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[7]	周丽丽, 施漪雯, 范建高, 孙超. 伴有ABCA1基因突变的青年代谢相关脂肪性肝硬化1例报道[J]. 实用肝脏病杂志, 2024, 27(4): 638-640.
[8]	曹焱芬, 邹昊轩, 谢艳. 体检人群血浆致动脉粥样硬化指数诊断代谢相关脂肪性肝病效能分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 361-365.
[9]	叶茜, 郑东, 杨昕宇, 郭江, 符美茵, 谢燕华, 刘洪. 超声衰减参数联合血清PAI-1和ALT水平评估代谢相关脂肪性肝病患者肝脂肪变性程度的价值分析^*[J]. 实用肝脏病杂志, 2024, 27(1): 44-47.
[10]	曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展[J]. 实用肝脏病杂志, 2023, 26(6): 769-772.
[11]	罗良德, 苏建明, 任成果, 申红. 复方甘草酸苷联合非诺贝特治疗代谢相关性脂肪性肝病患者疗效及其对脂代谢的影响^*[J]. 实用肝脏病杂志, 2023, 26(5): 650-653.
[12]	蔡欣, 辛春红, 牛洪凯, 兰春祥. 代谢相关脂肪性肝病患者血清HIF-1α、Chemerin和脂联素水平变化及临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 654-657.
[13]	熊印祥, 宦丽君, 刘巧. 代谢相关脂肪性肝病患者SLCO1B1和APOE基因多态性与脂代谢紊乱关系研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 206-209.
[14]	陈怡, 朱友, 周希乔. 甲状腺激素与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 145-148.
[15]	冯娟, 哈丽达·夏尔甫哈孜, 范晓棠, 任智慧, 才仁, 李亮, 何方平. 合并MAFLD的乙型肝炎肝硬化患者血清瘦素水平变化特点分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 536-539.